Skip to main content
Join CMKC members for a complimentary virtual event on December 10, 11am ET: CM MythBusters: https://bit.ly/3YXJynA. This is a fantastic opportunity to connect, collaborate, and debunk common myths about continuous manufacturing!
13.59.129.141

Tags: Von Hippel-Lindau (VHL) disease-associated tumors

Peer-reviewed journal (1-1 of 1)

  1. Evolution of a Green and Sustainable Manufacturing Process for Belzutifan: Part 4─Applications of Process Analytical Technology in Heterogeneous Biocatalytic Hydroxylation

    25 Jun 2024 | Contributor(s):: Qin, Yangzhong, Mattern, Keith A., Zhang, Victoria, Abe, Kotoe, Kim, Jungchul, Zheng, Michelle, Gangam, Rekha, Kalinin, Alexei, Kolev, Joshua N., Axnanda, Stephanus, Dance, Zachary E. X., Ayesa, Umme, Ji, Yining, Grosser, Shane T., Appiah-Amponsah, Emmanuel, McMullen, Jonathan P.

    Belzutifan has been approved recently by the U.S. Food and Drug Administration (FDA) for treating patients with certain types of Von Hippel-Lindau (VHL) disease-associated tumors. Although a commercial synthetic process has been established to make belzutifan, a further optimized process with...